mAChR2

The M2 muscarinic acetylcholine receptor (mAChR2) functions as a G protein-coupled receptor that regulates acetylcholine signaling in both neuronal and non-neuronal cells[1]. Mechanistically, M2 modulates presynaptic neurotransmitter release via coupling to protein kinase C (PKC) and PDK1, selectively influencing PKCβI and PKCε isoforms and downstream SNARE machinery[2]. In the neuromuscular junction, M2 participates in developmental synapse elimination by regulating activity-dependent acetylcholine release, coordinating with M1/M4 mAChRs and adenosine receptors[3][4]. Beyond the nervous system, M2 receptors control epithelial and immune cell functions, including endocytosis-mediated receptor trafficking and signaling regulation[1]. In cardiac myocytes, M2 activation triggers endothelial nitric oxide synthase (eNOS)-dependent nitration of p190A RhoGAP, enhancing RhoA activity and altering cytoskeletal dynamics[5]. In disease models, down-regulation of M2 adversely affects Alzheimer’s disease-relevant genes, including BACE1, and disrupts amyloid precursor protein processing[5][6]. Compared with related muscarinic isoforms, M2 uniquely suppresses BACE1 expression, whereas M1 activation increases it[6]. Pharmacologically, selective M2 inhibitors, such as methoctramine, can block agonist-induced signaling in smooth muscle and macrophages, providing tools for dissecting M2-specific pathways[7][8]. These characteristics render M2 a critical target for experimental modulation in studies of synaptic plasticity, neurodegeneration, cardiac physiology, and immune regulation[1][2][5].
References: